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Normal human keratinocytes, propagated as epithelial outgrowths in vitro, were exposed 
to different concentrations of methotrexate (MTX.) for different periods of time. After a 1-hr 
exposure, DNA synthesis was inhibited in a reversible manner. No change in the mitotic 
index was observed. Mter a 6-hr exposure, both DNA synthesis and mitosis were inhibited, 
again in a reversible fashion. Prolonged exposure (24 hr) resulted in irreversible mitotic 
inhibition even when followed by recovery periods of 168 hr. The effective concentrations of 
MTX in vitro were similar to those described p reviously in vivo. 
The mitotic-inhibiting properties of methotrex-
ate (MTX) have been exploited for many years in 
the treatment of psoriasis [1,2]. Much of our 
knowledge of the pharmacology of MTX comes 
from in vitro studies using nonepidermal cells. 
While the effect of MTX on human epidermis has 
been partially analyzed in vivo [3-5], there has 
been little analysis along similar lines using an in 
vitro system. Normal human epidermal keratino-
cytes can be propagated on artificial surfaces in 
vitro where, in the absence of underlying connec-
tive tissue, they produce a stratified, squamous 
epithelium showing basal cell proliferation and 
many of the morphologic and chemical changes 
characteristic of keratinization [ 6-8]. Proliferative 
events in this system can be studied with ease and 
the effects of drugs and pharmacologic agents 
evaluated [9]. The present investigation describes 
some responses of cultured human keratinocytes 
to MTX. 
MATERIALS AND METHODS 
The techniques for growing epithelial cell sheets of 
keratinocytes from explants of normal human skin 
have been described elsewhere [6-8]. For studies of the 
effect of MTX on mitosis and labeling index, 3 to 4 
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explants were placed on a single coverslip (multiple 
coverslips/experiment). For direct determination of in-
corporation of l 3H]deoxyuridine and [3H]thymidine into 
DNA, the technique of multiple (20) primary explants 
was used llO]. All studies were carried out on cells after 
10 to 12 days in vitro. Different experiments were per-
formed on skin from different donors. Thus, while each 
control and its experimental counterpart was carried 
out on skin from the same donor, skin from multiple 
donors was needed to provide sufficient material to 
evaluate all the factors described under Results. As 
pointed out. elsewhere \111, baseline rates of prolifera-
tion seem to vary in vitro according to the donor; but 
any effects of drugs on this baseline appear to be con-
sistent from donor to donor. 
MTX (Lederlel , diluted with culture fluid , was added 
in a variety of final concentrations. Details oflength of 
exposure, recovery period, etc., are described under 
Resulls. The mitotic index (M.l.l is the ratio of number 
of mitotic figures to interphase nuclei and was deter-
mined by a method described elsewhere [12]. To deter-
mine the labeling index (L.I.l, i.e. , the percentage of 
cells in DNA synthesis, [3H]thymidine (sp act 6.7 Ci/ 
IDM) or [3H]deoxyuridine (sp act 10 Ci/mM) was added at 
a level of 2 JLCi/ml to cultures for 1 hr foll owed by 
fixation and autoradiography [13]. All exposures fol-
lowing dipping in emulsion (Kodak NTB-2) were at 4•c 
for 2 weeks. The ratio oflabeled to unlabeled interphase 
nuclei was determined for a total of 1000 cells per out-
growth. Quantitative measurement of incorporation of 
[ 3H)thymidine or [3 H)deoxyuridine inLo DNA by scintil-
lation counting has been described elsewhere 110]. 
RESULTS 
Experiments in which keratinocytes were ex-
posed for 24 hr to different concentrations of MTX. 
showed that 0.1 or 1.0 IJ.g{ml was always effective 
in causing nearly total mitotic inhibition. There 
was no effect using 0.01 IJ.g/ml. The 1.0 J.tg/ml level 
was chosen for most subsequent experiments. 
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TABLE I. Effect of different durations of exposure to MTX (1 p.glml) on M 1 . and L.I . 
Controls (no MTX) had culture fluid changed at same time as experimentals when MTX was washed out in 
recovery experiments. Horizontal lines dividing Table serve to group experiments performed on cultures from skin 
of the same donor. The entire series was repeated two times on skin from other donors and the same results were 
obtained. 
Duration of exposure 
to MTX (hr) 
Recovery period 
(hr) M.l. :;: SD 
0 0 26::!: 1 
0 29 ::!: .5 
0 24 16 ::!: .5 
24 18 ::!: 0 
0 0 31.9 ::!: 4 
6 0 13.5 ::!: 7 
0 24 28.7 ::!: 3 
6 24 39.8 ± 5 
0 0 4.4 ± 6 
24 0 4 ::!: 2 
0 24 37 ::!: 2 
24 24 0 
0 48 38 ::!: 3 
24 48 2 ± 0 
0 168 15 ± 4 
24 168 0 
Table I shows the results of several experiments 
using MTX at a concentration of 1 J.Lg/ml. A 1-hr 
exposure to the drug caused no change in the M.I. , 
but did decrease the L.I. using [3H)deoxyuridine 
by greater than 90%. l:1H]deoxyuridine can be used 
as a marker for de novo DNA synthesis 14). The 
absence of an effect on the M.I. results from the 
continued movement of cells from G2 into M, the 
former having a value of abou t 7 hr in this system 
ll3]. Thus, the effect on DNA synthesis is not yet 
reflected in the M.I. after a 1-hr exposure to MTX. 
If MTX was washed out and the cells allowed to 
recover for 24 hr, the L.l. (f3H]deoxyuridine) re-
turned to control values. Thus, the drug had a 
rapid, reversible effect on suppression of DNA 
synthesis. 
A 6-hr exposure to MTX (Tab. 1) resulted in a 
58% decrease in M .I. During this exposure, many 
of the cells in G2 have passed into and through M 
but no new cells have moved through S into G~ due 
to the block by MTX. Those mitoses present proba-
bly derive from cells that were in early G~ at the 
time MTX was added. The L.I. (L3H]deoxyuridine) 
was again decreased to zero. If MTX was washed 
out and a 24-hr recovery in normal culture fluid 
allowed, both the M.I. and L.I. (13H]deoxyuridine) 
returned to values slightly above those of the con-
trols. Thus, the effects of a 6-hr exposure to 1 
J.Lg/ml of MTX also appeared to be reversible. 
Twenty-four-hour exposure to MTX (Tab. I) re-
sulted in almost total suppression of mitotic activ-
ity. While the L.l. (l3HJdeoxyuridine) was also 
nearly zero, the L.I. ((3H]thymidine) more than 
doubled. [3H)Thymidine, which is also a marker 
for DNA synthesis, can be incorporated into DNA 
in the presence of MTX via an alternate salvage 
pathway, thereby avoiding the enzymatic block 
L.I. ( %) f3H]deoxyurid.ine 
16.2 
1.0 
16.0 
15.0 
19.8 
0 
17.9 
21.3 
19.2 
.1 
7.0 
0.5 
6.6 
0.14 
5.9 
1.4 
L.l. 1%) (3H]thymid.ioe 
20.0 
42.0 
8.5 
12.1 
4 .9 
10.8 
5.9 
0.8 
TABLE II. Effects o{24-hr exposure to 2.5 p.g/ml MTX 
on incorporation ofi"H}deoxy uridin.e an.d !"Hl thym.idine 
into DNA (cpm/p.g DNAJ 
Each value represents the average for two dishes of 
ce!Js. The entire experiment was repeated and the re-
sults were confirmed. 
[ 3H)Deoxyuridi ne 
[ 3HJ1'hymidine 
Control 
2610 
6213 
Experimemal 
1547 
22,865 
caused by the drug. The autoradiographic re-
sults were confirmed by direct determination of 
the amount of raclioactive precursor incorporated 
into DNA using both (3H)thymidine and PHJ-
deo>..")'Uridine (Tab. li) . It should be noted that 
autoradiography provides a relatively crude meas-
ure of labeled precursor incorporation. For exam-
ple, a L.I. of nearly zero with l3H]deoxyuridine 
after 24 hr with 1 11-g/ml of MTX (Tab. I) corre-
lated with a decreased but still significant incorpo-
ration of r'Hldeoxyuridine into DNA as measured 
by scintillation counting after 2.5 J.Lglml of MTX 
(Tab. II). In other experiments, MTX was washed 
out after 24 hr and clifferent groups of treated cells 
were allowed to r ecover for 24, 48, or 168 hr (Tab. 
I). In all cases the M.I. remained at zero or only 
slightly above even though some incorporation of 
L3H]thymidine and I3H)deoxyuridine continued. 
Since a 6-hr exposure to MTX resulted in 
reversible depression of mitosis and DNA synthe-
sis, which is similar to in vivo effects in psoriasis 
l4], it was of interest to determine the source of the 
dividing cells seen after the recovery period. The 
fate of the MTX-inhibited cells was studied by 
prelabeling with [3H)thymidine. One hour prior to 
adding M"'X, [3H]thymidine was added and then 
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washed out thoroughly with three rinses of "cold" 
culture fluid. MTX was added for 6 hr, washed out 
for 24 hr, and the cultures fixed. Many labeled 
mitotic figures were found, indicating that al-
though cells in S phase had been blocked tempor-
arily in DNA synthesis, they were able to recover 
completely and proceed on to mitosis. Occasional 
labeled pyknotic nuclei were found which probably 
derived from cells that did not recover or else from 
recovered postmitotic cells that had keratinized. 
DISCUSSION 
Studies of MTX in the treatment of cancer have 
been carried out first in vivo and then compli-
mented and greatly extended by in vitro observa-
tions. The use of MTX in treatment of a benign 
disease such as psoriasis has been accompanied by 
a series of studies in vivo that have provided much 
valuable information recording effects of the drug 
on keratinocyte proliferation 13-5]. There has, 
however, been very little work attempted in vitro 
to corroborate and extend the in vivo findings. 
Indeed, Karasek [14] reported that, compared 
with other water-soluble antimetabolites in vitro, 
MTX was quite ineffective in blocking growth of 
human keratinocytes, even at a concentration of 
1000 J.Lg/ml. Quite clearly our own study shows 
this not to be the case and, in fact, normal human 
keratinocytes in vitro seem to be susceptible to the 
same range of concentrations of MTX as are effec-
tive in vivo L4,15,16] and for other types of cells in 
vitro L17-19]. A possible explanation for the differ-
ence between our findings and those of Karasek 
may lie in the method of analysis. Karasek mea-
sured gross changes in size of keratinocyte out-
growths whereas we looked specifically for 
changes in cytologic and biochemical parameters. 
The characteristics of reversible inhibition and 
recovery from short exposure to MTX in vitro for 
normal keratinocytes compare closely with the re-
covery characteristics described in psoriasis in 
vivo 14]. It has been reported that concentrations 
ofMTX which inhibit DNA synthesis or are lethal 
for psoriatic keratinocytes in vivo 151 and in organ 
culture in vitro L20] have less inhibition and no 
serious damaging effect on normal keratinocytes. 
Our preliminary studies of psoriatic keratinocytes 
in outgrowth cultures show responses to MTX 
identical to those of normal keratinocytes. Thus, 
the so-called selective effect of MTX may reflect 
only as-yet unidentified in vivo environmental fac-
tors not present in vitro. This correlates well with 
other data that suggest there is no inherent differ-
ence between normal and psoriatic keratinocytes 
[9]. 
While many mitoses found 24 hr after a 6-hr 
exposure and washout of MTX may have repre-
sented cells previously in G1 which were not af-
fected by the drug and then entered S phase, G2 , 
and M during the recovery period, some repre-
sented cells previously blocked in S phase which 
then recovered. This was shown by prelabeling 
with I3H]thymidine. Although a few labeled pyk-
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notic nuclei were found, most postrecovery label 
was present in interphase nuclei or over readily 
identified metaphase chromosomes. Similar ex-
periments in vivo have stressed the presence of 
labeled pyknotic nuclei in MTX-treated psoriasis 
lesions [5], indicating that a proportion of blocked 
cells do not recover. Since the present in vitro 
studies show that keratinocyte recovery is possi-
ble, the effect of MTX in psoriasis probably is due 
only partially to its cell-killing ability, the re-
mainder being related to a reversible prolongation 
of the cell cycle. It should be noted that a 6-hr 
exposure to 1 J.Lg/m1 of MTX in vib·o probably 
approximates the in vivo exposure following par-
enteral MTX inasmuch as tissue levels of the drug 
have been measured at 0.46 to 0.85 p.g/grn 5 hr 
after injection [16[. 
More prolonged exposure to MTX was followed 
by irreversible mitotic inhibition , even though "re-
covery" periods of up to 1 week were allowed. This 
was consistent with observations in other systems 
that "toxicity depends on duration of exposure to 
specific inhibitory levels of drug" 1211. Recovery 
took place in culture fluid containing folic acid (1 
J.Lg/ml in Eagle's minimal essential medium plus 
additional folic acid in serum). There was an in-
creased L .I. WHJthymidine) and incorporation of 
[:1Hlthymidine into DNA after 24 hr with MTX 
which clearly bore no relation to the actual state of 
health of the cells since mitotic recovery never 
took place. The higher L .l. WHJthymidine) even 
persisted after the 24-hr and 48-hr recovery period, 
eventually dropping off drastically by 168 hr. A 
similar increase in L.I. (L=iHJthymidinel has been 
noted in psoriasis after MTX 141 and interpreted as 
a sign that the cells were not dying. Clearly, that 
interpretation is not supported by the present in 
vitro studies. 
The increased incorporation of [:1H]thymidine 
directly int.o DNA in the face of a block by MTX 
apparently takes place via the "salvage" pathway 
[22] and reflects compensation for inhibition at the 
level of the "de novo" pathway. The importance of 
the de novo pathway in human skin has been 
stressed [23], although the salvage pathways to 
DNA synthesis may be more important in the skin 
of other species l24j. Failure of cells to recover 
following a 24-hr exposure to MTX may not be 
related only to a prolonged block in DNA synthesis 
but also to inhibition of other path ways dependent 
on 1-carbon units which leads to overall cell decay 
117 ,25,26]. Many st-udies have stressed the pri-
mary role of MTX as an inhibitor of dihydrofolic 
acid reductase (DHFA reductase), thereby limit-
ing the availability of reduced folate for synthesis 
of thymidine monophosphate CTMP) from deoxy-
uridine monophosphate (DUMP) in the de novo 
synthesis of DNA [20,27,28]. A portion of MTX is 
tightly, but reversibly, bound to DHF A reductase 
L29J. The most. important inhibitory effect of the 
drug, however, may be related to the level of ex-
cess free MTX which interacts with a "low-affin-
ity" receptor site 1301. Effects on other aspects of 
Feb. 1977 
metabolism have also been demonstrated and in-
clude direct inhibition of thyrnidylate synthetase 
[17), and inhibition of synthesis of purines 125], 
RNA 126], and proteins 131]. The relative contribu-
tion of each of these effects to mitotic inhibition or 
cell killing has been discussed \18). Since the cell 
cycle in the keratinocyte in vitro system is about 
59 hr [13], after 24-hr exposure to MTX a sizeable 
cell population would still exist outside ofS phase, 
and the DNA synthesis of these cells would not be 
affected by the drug. This suggests that the other 
aspects of ce]J metabolism are affected to the point 
of irreversible recovery. 
The present experiments point out that human 
keratinocytes in vitro show a sensitivi ty and be-
havior to MTX quite similar to that of keratino-
cytes from patients with psoriasis in vivo. It seems 
possible. therefore, that this in vitro system may 
be of real use in the screening and evaluation of 
other drugs of potentiaJ value in treatment of skin 
disease. 
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